Clinical trial · Observational
The Real Word Study of Albumin-binding Taxol for Lung Cancer Treatment
NCT03802409CI-TRIAL-00036647unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators conduct the real world study to explore the efficacy and safety of Albumin-binding taxol in lung cancer .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progress free survival
- timeFrame
- 1 year
- description
- Progress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.
Secondary outcomes (3)
- measure
- Overall Survival
- timeFrame
- 3 year
- description
- overall survival is defined as the length of time from random assignment to death or to last contact.
- measure
- disease control rate
- timeFrame
- 1 year
- description
- Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female patients . 2. Confirmed by Histopathology or Cytology of Lung Cancer 3. Patients should be voluntary to the trial and provide with signed informed consent 4. The researchers believe patients can benefit from the study. Exclusion Criteria: 1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to Albumin-binding taxol or its accessories 2. Pregnant or lactating women 3. Patients with Albumin-binding taxol contraindications 4. Patients of doctors considered unsuitable for the trial
References
Publications (0)
Data not yet available
No reference posted for this study.